Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript Summary
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript Summary
G&A expenses marginally decreased from CHF 0.6 million in Q3 2023 to CHF 0.5 million in Q3 2024. The following is a summary of the Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript:
以下是Addex Therapeutics Ltd (ADXN) 2024年第三季度業績會議呼叫交易摘要：
Financial Performance:
財務表現：
Addex recognized Q3 2024 income of CHF 0.1 million primarily from research funding, compared to CHF 0.3 million in Q3 2023.
R&D expenses declined due to completion of search phase, resulting in lower costs, from CHF 0.5 million in Q3 2023 to CHF 0.2 million in Q3 2024.
G&A expenses marginally decreased from CHF 0.6 million in Q3 2023 to CHF 0.5 million in Q3 2024.
Diluted net loss from investments in Neurosterix was CHF0.9 million.
Addex主要通過研究資金獲得了2024年第三季度10萬瑞士法郎的收入，而2023年第三季度爲30萬瑞士法郎。
研發費用下降，由於研究階段的完成，導致成本降低，從2023年第三季度的50萬瑞士法郎降至2024年第三季度的20萬瑞士法郎。
管理及行政費用稍微從2023年第三季度的60萬瑞士法郎減少至2024年第三季度的50萬瑞士法郎。
在神經固醇投資方面，稀釋後的淨損失達到了90萬瑞士法郎。
Business Progress:
業務進展：
Progress in the GABAB PAM program for substance use disorders with IND-enabling studies started by partner Indivior.
Independent research advancing with GABAB PAM program for chronic cough, with preclinical proof-of-concept and toxicity studies completed.
Strategic advance in dipraglurant development targeting brain injury recovery.
Continued advancements with spin-out company Neurosterix, focusing on IND-enabling studies for their M4 PAM program.
通過合作伙伴Indivior啓動了用於物質使用障礙的GABA b PAm項目的IND啓動研究。
獨立研究正在進行GABAb PAm程序，用於慢性咳嗽，已完成前期概念證明和毒性研究。
在迪普拉古蘭特（dipraglurant）開發方面取得戰略進展，瞄準大腦受傷康復。
與分拆公司Neurosterix繼續前進，專注於爲其M4 PAm項目進行IND啓動的研究。
Opportunities:
機會：
Engagement in high-impact clinical programs such as substance use disorders and chronic cough, addressing substantial unmet medical needs.
Potential financial gain from partnership with Indivior, encompassing up to $330 million in milestone payments.
參與高影響力的臨床項目，如物質使用障礙和慢性咳嗽，解決重大的醫療需求。
與Indivior合作可能帶來財務收益，涉及高達33000萬美元的里程碑付款。
Risks:
風險：
Reliance on financing to progress key clinical programs, including the GABAB PAM development for chronic cough set to commence IND-enabling studies in 2025.
依靠融資推動關鍵臨床項目的進展，包括爲慢性咳嗽開發的GABAb PAm項目，將於2025年啓動IND啓動研究。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
